These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32581304)

  • 1. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
    Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
    Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
    Rothenburger T; Thomas D; Schreiber Y; Wratil PR; Pflantz T; Knecht K; Digianantonio K; Temple J; Schneider C; Baldauf HM; McLaughlin KM; Rothweiler F; Bilen B; Farmand S; Bojkova D; Costa R; Ferreirós N; Geisslinger G; Oellerich T; Xiong Y; Keppler OT; Wass MN; Michaelis M; Cinatl J
    J Exp Clin Cancer Res; 2021 Oct; 40(1):317. PubMed ID: 34641952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
    Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
    Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
    Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
    Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
    Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T
    Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
    Curbo S; Karlsson A
    Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
    Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
    Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
    Miller LH; Maxa KL; Winter SS; Gossai NP
    Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanine arabinoside as a bone marrow-purging agent.
    Kurtzberg J
    Ann N Y Acad Sci; 1993 Jun; 685():225-36. PubMed ID: 8363226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
    Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
    Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
    J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.